NASDAQ:CYCN Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis $3.53 -0.17 (-4.59%) As of 09:30 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Cyclerion Therapeutics Stock (NASDAQ:CYCN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cyclerion Therapeutics alerts:Sign Up Key Stats Today's Range$3.60▼$3.7250-Day Range$2.98▼$3.9352-Week Range$1.03▼$8.48Volume7,542 shsAverage Volume21,607 shsMarket Capitalization$15.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need. The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction. In parallel, Cyclerion is advancing CY6463, a central nervous system-penetrant sGC stimulator, in neurocognitive and neurodegenerative disorders. Both programs are supported by preclinical and early-stage clinical data suggesting potential benefits in modulating cGMP signaling across multiple organ systems. Cyclerion leverages a modular research platform to optimize pharmacokinetic and pharmacodynamic properties for both systemic and brain-targeted therapies. Founded in May 2018 as a spin-out from Ironwood Pharmaceuticals, Cyclerion is headquartered in Cambridge, Massachusetts, with research collaborations and clinical sites spanning the United States and Europe. The company is led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs. Cyclerion continues to build on its translational science capabilities to expand its pipeline of sGC-based therapeutics and explore strategic partnerships to advance its programs toward regulatory milestones.AI Generated. May Contain Errors. Read More Cyclerion Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreCYCN MarketRank™: Cyclerion Therapeutics scored higher than 9% of companies evaluated by MarketBeat, and ranked 1615th out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCyclerion Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCyclerion Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Cyclerion Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cyclerion Therapeutics are expected to grow in the coming year, from ($1.20) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclerion Therapeutics is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclerion Therapeutics is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclerion Therapeutics has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cyclerion Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.75% of the float of Cyclerion Therapeutics has been sold short.Short Interest Ratio / Days to CoverCyclerion Therapeutics has a short interest ratio ("days to cover") of 1.86, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclerion Therapeutics has recently increased by 3.83%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCyclerion Therapeutics does not currently pay a dividend.Dividend GrowthCyclerion Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Cyclerion Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders34.30% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cyclerion Therapeutics' insider trading history. Receive CYCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYCN Stock News HeadlinesCyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s PipelineApril 21, 2026 | finance.yahoo.comPenny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?April 2, 2026 | finance.yahoo.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.July 22 at 1:00 AM | Profits Run (Ad)SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)April 2, 2026 | prnewswire.comCyclerion to combine with Korsana Biosciences in $380 million merger dealApril 2, 2026 | msn.comCyclerion provides public listing vehicle for Korsana in $380M dealApril 2, 2026 | bizjournals.comCYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its ShareholdersApril 2, 2026 | businesswire.comShareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public ShareholdersApril 1, 2026 | prnewswire.comSee More Headlines CYCN Stock Analysis - Frequently Asked Questions How have CYCN shares performed this year? Cyclerion Therapeutics' stock was trading at $1.27 on January 1st, 2026. Since then, CYCN shares have increased by 190.6% and is now trading at $3.69. How were Cyclerion Therapeutics' earnings last quarter? Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.76) EPS for the quarter, topping analysts' consensus estimates of ($17.20) by $16.44. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative trailing twelve-month return on equity of 62.10%. When did Cyclerion Therapeutics' stock split? Cyclerion Therapeutics shares reverse split before market open on Tuesday, May 16th 2023.The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Cyclerion Therapeutics? Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cyclerion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclerion Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), GE Aerospace (GE), Advanced Micro Devices (AMD), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings5/12/2026Today7/22/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 CYCN's financial health is in the Green zone, according to TradeSmith. CYCN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYCN CIK1755237 Webwww.cyclerion.com Phone(857) 327-8778FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.53 million Net Margins-170.11% Pretax Margin-264.73% Return on Equity-62.10% Return on Assets-55.14% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.80 Sales & Book Value Annual Sales$1.99 million Price / Sales7.67 Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book1.53Miscellaneous Outstanding Shares4,330,000Free Float2,845,000Market Cap$15.28 million OptionableNo Data Beta1.74 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:CYCN) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersBofA: Digital Dollar Coming 2025-2030A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in se...Decentralized Masters | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredElon says “don’t save money.” Is he right?Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
